1.98 USD
▲-0.03+5.04%
盘后 1.89 +0.27%
2026-08-03
市值
$356.57M
市盈率
—
EPS
-0.40
股息率
—
52 周区间
1.61 – 6.88
成交量
3.05M
Beta
0.82
目标价
8.50
52W 低 1.6152W 高 6.88
价格走势
公司简介
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company’s lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; C...